Addition of Wood Group's electric submersible pumps and surface wellhead products:
*Provides GE with entry into the fast growing demand for enhanced oil recovery from mature oil fields using downhole pump 'artificial lift' in brownfield developments;
*Expands GE's high-technology product and service offering in unconventional oil and gas production, with significant applications for shale gas production;
Addition of Wood Group's electric submersible pumps and surface wellhead products:
*Provides GE with entry into the fast growing demand for enhanced oil recovery from mature oil fields using downhole pump 'artificial lift' in brownfield developments;
*Expands GE's high-technology product and service offering in unconventional oil and gas production, with significant applications for shale gas production;
FAIRFIELD, Conn.--11 February 2011-- The Board of Directors of General Electric Company (NYSE: GE) today authorized a regular quarterly dividend of $0.14 per outstanding share of the Company's common stock. The dividend is payable April 25, 2011 to shareowners of record at the close of business on February 28, 2011. The ex-dividend date is February 24, 2011.
New Hyperbaric Test Chamber Simulates Extreme Deepwater Conditions, Enabling Step-Change in Oil and Gas Industry Safety, Reliability and Performance
NAILSEA, UNITED KINGDOM---February 11, 2011---Demonstrating its continued commitment to subsea equipment safety, reliability and performance, GE Oil & Gas today officially opened both its new Hyperbaric Testing Hall and a newly refurbished Electrical & Electronics Assembly Plant in Nailsea, United Kingdom.
New Hyperbaric Test Chamber Simulates Extreme Deepwater Conditions, Enabling Step-Change in Oil and Gas Industry Safety, Reliability and Performance
NAILSEA, UNITED KINGDOM---February 11, 2011---Demonstrating its continued commitment to subsea equipment safety, reliability and performance, GE Oil & Gas today officially opened both its new Hyperbaric Testing Hall and a newly refurbished Electrical & Electronics Assembly Plant in Nailsea, United Kingdom.
Technology Designed to Allow Taller Towers while Lowering Wind Farm Installation and Transportation Costs
SCHENECTADY, N.Y.--11 February 2011-- GE (NYSE: GE) announced today the acquisition of next generation technology from Wind Tower Systems, LLC (WTS) that is expected to enable taller wind turbine towers. The need for taller, cost-efficient towers is becoming an important factor in the wind industry as blade lengths increase.
BETHESDA, Md.--11 February 2011-- GE Capital, Healthcare Financial Services announced today that it is agent and a lender for $55 million in senior secured credit facilities for eBioscience, Inc. The credit facilities will be used to finance the company's repurchase of certain shares from early investors, refinance existing debt, and provide growth capital. The financing includes a $45 million term loan and a $10 million revolving line of credit. GE Capital Markets served as sole lead arranger and bookrunner.
Washington, D.C.---February 10, 2011---Today the U.S. Court of Appeals for the Federal Circuit heard arguments in GE's (NYSE: GE) patent dispute against Mitsubishi Heavy Industries, Ltd. (MHI) for certain wind turbine technologies that GE alleges MHI has infringed. GE spokesman Dan Nelson released the following statement:
"Today's hearing was about one issue---the protection of GE's intellectual property.
* Medical errors remain the 8th leading cause of death in the United States, costing an estimated $29 billion and resulting in as many as 98,000 patient deaths per year. [1]
* GE's PSO will be one of the nation's largest Patient Safety Organizations.
* GE's PSO helps healthcare providers improve patient safety by pinpointing the root causes of risk and creating a community working to mitigate those risks.
BETHESDA, Md.--10 February 2011-- GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender and agent, a $12.5 million senior secured multi-draw term loan facility to Oncothyreon Inc. The financing provides the company with working capital to support clinical development activities.
